ATL 1102

Drug Profile

ATL 1102

Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics; Childrens Hospital Los Angeles
  • Class Anti-inflammatories; Antirheumatics; Antisense oligonucleotides
  • Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis
  • Preclinical Cancer
  • No development reported Asthma
  • Discontinued Stem cell mobilisation; Vertigo

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in Australia (Inhalation, Aerosol)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in China (SC, Injection)
  • 15 Feb 2016 Antisense intends to file an IND application with the US FDA for Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top